G Scott Chandler

9PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Apr 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Apr 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.

Chester Kao, Soren Charmsaz, Hua-Ling Tsai

|Mar 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

|Jan 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.

Stephanie L Alden, Soren Charmsaz, Howard L Li

Pageof 2

Frequent Collaborators

6 joint publications

Won Jin Ho

6 joint publications

Christopher Thoburn

5 joint publications

Howard L Li

5 joint publications

Evan J Lipson